Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

HIV infection in older adults

Nathalie Casau-Schulhof, MD
Section Editor
John G Bartlett, MD
Deputy Editor
Allyson Bloom, MD


Most of the literature on HIV infection in older adults defines older as ≥50 years of age. With the increasing survival of HIV-infected patients on antiretroviral therapy (ART) and increased case finding with wider HIV screening, the proportion of HIV-infected patients in this older age bracket has increased substantially [1]. The same recommendations on management of HIV infection in adults and adolescents apply to older adults as well, but certain issues are of particular importance in this population:

Epidemiology, risk factors, and delays in diagnosis due to unsuspected HIV infection

Antiretroviral use in the older population (pharmacokinetics and polypharmacy)

Age-related differences in immune responses to HIV and ART

HIV-related mortality


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jan 4, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA 2013; 309:1397.
  2. Joint United Nations Programme on HIV/AIDS. The Gap Report. September 2014 http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf (Accessed on May 20, 2015).
  3. Mack KA, Ory MG. AIDS and older Americans at the end of the Twentieth Century. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S68.
  4. Centers for Disease Control and Prevention. HIV Surveillance Report, 2013; vol. 25. Published February 2015. http://www.cdc.gov/hiv/library/reports/surveillance/ (Accessed on February 26, 2015).
  5. Hontelez JA, Lurie MN, Newell ML, et al. Ageing with HIV in South Africa. AIDS 2011; 25:1665.
  6. Levy JA, Ory MG, Crystal S. HIV/AIDS interventions for midlife and older adults: current status and challenges. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S59.
  7. Centers for Disease Control and Prevention. Diagnoses of HIV infection among adults aged 50 years and older in the United States and dependent areas, 2007–2010. HIV Surveillance Supplemental Report 2013;18(No. 3). Published February 2013. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplemental (Accessed on March 01, 2015).
  8. Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357:762.
  9. Levy BR, Ding L, Lakra D, et al. Older persons' exclusion from sexually transmitted disease risk-reduction clinical trials. Sex Transm Dis 2007; 34:541.
  10. Qaseem A, Snow V, Shekelle P, et al. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med 2009; 150:125.
  11. Moyer VA on behalf of the U.S. Prentive Services Task Force. Screening for HIV: U.S. Preventive services task force recommendation statement. Ann Intern Med 2013.
  12. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.
  13. Stone VE, Bounds BC, Muse VV, Ferry JA. Case records of the Massachusetts General Hospital. Case 29-2009. An 81-year-old man with weight loss, odynophagia, and failure to thrive. N Engl J Med 2009; 361:1189.
  14. Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010; 24:2109.
  15. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795.
  16. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373:808.
  17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on April 08, 2015).
  18. Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410.
  19. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1 (Accessed on September 30, 2015).
  20. Guidelines. European AIDS Clinical Society. Version 8.0. October 2015. http://www.eacsociety.org/files/2015_eacsguidelines_8.0-english_revised-20151104.pdf (Accessed on October 31, 2015).
  21. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA 2010; 304:1592.
  22. Rhee MS, Greenblatt DJ. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Pharmacol 2008; 48:1212.
  23. Vinikoor MJ, Joseph J, Mwale J, et al. Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia. AIDS Res Hum Retroviruses 2014; 30:949.
  24. Althoff KN, Justice AC, Gange SJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010; 24:2469.
  25. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029.
  26. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290.
  27. Semeere AS, Lwanga I, Sempa J, et al. Mortality and immunological recovery among older adults on antiretroviral therapy at a large urban HIV clinic in Kampala, Uganda. J Acquir Immune Defic Syndr 2014; 67:382.
  28. Yamashita TE, Phair JP, Muñoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735.
  29. Wellons MF, Sanders L, Edwards LJ, et al. HIV infection: treatment outcomes in older and younger adults. J Am Geriatr Soc 2002; 50:603.
  30. Wutoh AK, Brown CM, Kumoji EK, et al. Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. J Natl Med Assoc 2001; 93:243.
  31. Wutoh AK, Elekwachi O, Clarke-Tasker V, et al. Assessment and predictors of antiretroviral adherence in older HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S106.
  32. Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167:684.
  33. Ghidei L, Simone MJ, Salow MJ, et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging 2013; 30:809.
  34. Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS 2001; 15:1591.
  35. Lodwick RK, Smith CJ, Youle M, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22:1039.
  36. Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol 2013; 9:573.
  37. Crawford KW, Spritzler J, Kalayjian RC, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26:635.
  38. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66:2107.
  39. Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc 2014; 62:447.
  40. Edwards JK, Cole SR, Westreich D, et al. Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clin Infect Dis 2015; 61:1189.
  41. Davis DH, Smith R, Brown A, et al. Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adults. Age Ageing 2013; 42:520.
  42. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51.
  43. Fatti G, Mothibi E, Meintjes G, Grimwood A. Antiretroviral treatment outcomes amongst older adults in a large multicentre cohort in South Africa. PLoS One 2014; 9:e100273.
  44. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59:1787.
  45. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120.
  46. Greene M, Covinsky KE, Valcour V, et al. Geriatric Syndromes in Older HIV-Infected Adults. J Acquir Immune Defic Syndr 2015; 69:161.
  47. Aberg JA. Aging, inflammation, and HIV infection. Top Antivir Med 2012; 20:101.
  48. Somsouk M, Estes JD, Deleage C, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS 2015; 29:43.
  49. Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS 2015; 29:1263.
  50. Hattab S, Guiguet M, Carcelain G, et al. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. HIV Med 2015; 16:553.
  51. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.
  52. Cao W, Jamieson BD, Hultin LE, et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009; 50:137.
  53. Decrion AZ, Varin A, Drobacheff C, et al. A subset of functional effector-memory CD8+ T lymphocytes in human immunodeficiency virus-infected patients. Immunology 2007; 121:405.
  54. Stone, SF. HIV Med 2005; 6:399.
  55. Nkhoma, E, Vannappagari, V, Mynepalli, L, Logie, J. Comorbidities and coinfections among HIV patients 50 years and older. First International Workshop on HIV and Aging. October 4-5, 2010. Baltimore. Abstract O_16.
  56. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45:1074.
  57. Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292.
  58. Berry SA, Fleishman JA, Moore RD, et al. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr 2012; 59:368.
  59. Wilkie FL, Goodkin K, Khamis I, et al. Cognitive functioning in younger and older HIV-1-infected adults. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S93.
  60. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63:822.
  61. Cohen RA, Seider TR, Navia B. HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther 2015; 7:37.
  62. Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011; 25:919.
  63. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010; 153:452.
  64. Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21:617.
  65. Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005; 41:1794.
  66. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183:388.
  67. Brothers TD, Kirkland S, Guaraldi G, et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis 2014; 210:1170.
  68. Guaraldi G, Brothers TD, Zona S, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS 2015; 29:1633.
  69. Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci 2011; 66:1030.
  70. Levett TJ, Cresswell FV, Malik MA, et al. Systematic Review of Prevalence and Predictors of Frailty in Individuals with Human Immunodeficiency Virus. J Am Geriatr Soc 2016; 64:1006.
  71. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013; 27:563.
  72. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr 2013; 62:149.
  73. Womack JA, Goulet JL, Gibert C, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis 2013; 56:1498.